Objective: To document the frequency and severity of various types of rashes seen with commonly used oral antibiotics in the pediatric outpatient setting.
A NTIBIOTICS, the most frequently prescribed pediatric outpatient drugs, are the cause of most druginduced adverse reactions in children. [1] [2] [3] Although most of these reactions are minor and transient [1] [2] [3] [4] and include various cutaneous manifestations, fatalities may occur and some of the reactions may necessitate pediatric inpatient care. 5 Furthermore, it is possible that these reactions could alter compliance and therapeutic outcomes, resulting in the administration of alternative antibiotics that may be more expensive and more likely to promote the emergence of resistant microbial strains.
There is a paucity of information on the prevalence, distribution, and types of cutaneous eruptions attributable to each of the commonly prescribed antibiotics in the outpatient setting, and the few available studies relate mostly to the adult population. Published studies 1, 6 specifically documenting the prevalence of these cutaneous adverse drug reactions (ADRs) associated with antibiotics are rare in the pediatric outpatient setting.
Where antibiotic-associated rashes have been examined along with various adverse reactions to other drugs, most researchers 2, 3 have considered the problem small and of minor consequences in their communities.
This study documents the frequency and severity of various types of rashes associated with commonly used oral antibiotics in the pediatric outpatient setting.
RESULTS
A total of 5923 patient medical records were reviewed. Of these, 1927 (32%) patients had no record of an antibiotic being prescribed while they were patients at VPA. An adverse reaction to 1 or more antibiotics was found on 509 (8.6%) of the 5923 medical records. Of these, 37 were discarded because records only documented minor gastrointestinal tract adverse effects or other minor symptoms with no rashes, leaving a total of 472 medical records with rashes recorded for the specific antibiotics. Three patients who developed urticaria to penicillin had similar rashes with erythromycin. No rashes were recorded for any of the newer macrolides (clarithromycin and azithromycin) or for tetracyclines, which were rarely prescribed. Of the 472 parental questionnaires sent, 284 (60%) were returned, of which 252 (89%) were evaluable. Of 45 records requested from outside physicians, only 15 (33%) were obtained. From the evaluable returned questionnaires and the outside records obtained, 62% of the rashes were physician verified, and these corroborated records at VPA. Table 1 shows the age and sex distributions of the children who developed a rash due to antibiotics. Of the 472 patients, 254 (53.8%) were boys. Of these boys, 237 (93.3%), and 178 (81.6%) of the 218 girls, were younger than 6 years at the time of the rash. The age of the patients ranged from 5 weeks to 18 years. Overall, there was no statistically significant difference between the boys and girls who reported a rash after receiving an antibiotic. However, there were significantly more rashes documented for boys younger than 3 years and for girls older than 9 years.
STUDY

ANTIBIOTIC PRESCRIPTION
There were 18867 antibiotic prescriptions for the 3996 patients whose records showed at least 1 antibiotic prescription at the time of occurrence of the rash. The average number of prescriptions per person was similar for the different antibiotics, as shown in Table 2 .
PATIENTS AND METHODS
SETTING
Vienna Pediatric Associates Ltd (VPA) is a private group practice in northern Virginia consisting of 5 boardcertified pediatricians. Approximately 12000 children (defined as those aged 0-18 years in this study) were active patients of the practice in 1996. There were nearly 20 000 outpatient visits to the office in that year. The most frequent diagnoses necessitating antibiotic therapy were acute otitis media, acute pharyngotonsillitis, and sinusitis.
MATERIALS
From March 1 to July 31, 1996, a trained research assistant (a third-year nursing student) carried out a survey of 50% of active patient records at VPA. The research assistant reviewed all the medical records to document the total number of oral antibiotic prescriptions written, the indications for the antibiotics, and patient demographics. Furthermore, the research assistant noted which patients were labeled as allergic to an antibiotic, the description of any rashes, and the dates of occurrence of the rash.
A written questionnaire with a prestamped envelope and a $2 bill was mailed to each parent of a child designated as having an ADR with an antibiotic. The questionnaire sought to gather information (based on parental recall) about the relation of the rash with administration of a specific antibiotic. It also asked for information about other symptoms that were induced by the antibiotic and about whether the rash had been confirmed as antibiotic related following examination by a physician.
In cases in which the rash occurred before the child became a patient at VPA, attempts were made to obtain copies of relevant records. An abbreviated questionnaire also was mailed to former physicians who attended to the children at the time an antibiotic-related rash occurred.
For this study, antibiotics were divided into 4 groups: (1) penicillins, including amoxicillin and the combination drug amoxicillin and clavulanate potassium; (2) sulfonamides, including the combination drugs trimethoprim and sulfamethoxazole and erythromycin ethylsuccinate and sulfisoxazole acetyl; (3) cefaclor; and (4) cephalosporin antibiotics excluding cefaclor. Only rashes documented with orally administered antibiotics in these categories were included.
The rashes were classified as (1) macular and/or papular drug exanthema; (2) hives, urticaria, welts, and/or angioedema; (3) erythema multiforme; and (4) indistinct other rashes. We classified serum sicknesslike reactions (SSLRs) as definite or probable. Definite SSLRs consisted of a rash with fever, joint pains, and swelling in relation to antibiotic administration for at least 7 days, while probable SSLRs were defined as a rash with fever and joint manifestations documented with antibiotic given for less than 7 days. This classification is arbitrary and is based on the fact that SSLRs typically occur 7 to 10 days following exposure to the offending medication. [6] [7] [8] If a child developed a rash to more than 1 antibiotic, the antibiotics were enumerated singly. Visual verification by a physician was required for designation as macular and/or papular drug exanthema or an erythema multiforme rash, but parental telephone description of pruritic urticaria and/or angioedema without physician confirmation at an office visit was permitted.
To further validate the data and ensure consistency and accuracy, 2 of us (E.O.I. and B.L.W.) separately scrutinized all the raw data and the returned survey questionnaires. A rash was considered as "indistinct other" if there was lack of documentation of morphologic features on the record or lack of agreement between the 2 researchers regarding its morphologic class.
STATISTICS
Using computer software (Epi Info, Version 6.04a; Centers for Disease Control and Prevention, Atlanta, Ga, and World Health Organization, Geneva, Switzerland), odds ratios were calculated for the observed differences in the age and sex distribution of children with rashes compared with the total number of children in the practice. Confidence intervals were calculated around the frequencies of rashes documented with the prescribed antibiotics, and a 2-sample z test was used to compare differences in these frequencies. PϽ.05 was considered statistically significant.
(REPRINTED) ARCH DERMATOL / VOL 136, JULY 2000 WWW.ARCHDERMATOL.COM 850 Table 2 also shows the frequency of rashes with exposure to the various groups of antibiotics. A statistically higher frequency of rashes is documented for cefaclor than for the other antibiotics. Similarly, a significantly higher frequency of rashes was recorded with sulfonamides than with penicillins. Cephalosporins, other than cefaclor, were associated with the lowest rate of rashes. When the data were analyzed using the number of patients who received the different groups of antibiotics as the denominator, a similar pattern emerged, but with a higher frequency of rashes. Rashes were recorded in 12.3%, 7.4%, 8.5%, and 2.6% of children who received cefaclor, penicillins, sulfonamides, and other cephalosporins, respectively. Overall, rashes were documented in 7.3% of the children who received these antibiotics (the frequency of rashes per patient is not shown in Table 2 ). The frequency of rashes documented for cefaclor was statistically higher than for all other groups of antibiotics, but significantly more rashes were also recorded for sulfonamides than for penicillins.
The distribution and description of the various types of rashes are shown in Table 3 . Rashes described as urticaria, hives, or welts and the macular and/or papular drug exanthemas were the most common types, each accounting for 208 (45.9%) of the 453 describable rashes. Table 4 is a breakdown of the rashes recorded with cephalosporins, other than cefaclor. There were no statistically significant differences within this group except that significantly more rashes were recorded with cefixime than with cefuroxime axetil.
SERUM SICKNESSLIKE REACTIONS
There were 31 cases of SSLRs. Twelve of these were regarded as definite, while 19 were considered probable.
The rates of SSLRs documented with the antibiotics are shown in Table 5 . Again, compared with others, significantly more SSLRs were recorded with cefaclor than with other antibiotics.
HOSPITALIZATION AND MORTALITY
No cases of Stevens-Johnson syndrome or toxic epidermal necrolysis occurred among any of the children with a rash. There were no deaths, and none of the children with rashes due to antibiotics required hospitalization.
COMMENT
Adverse drug reactions are common and have a significant impact on the health care system. 9 In 1994, approximately 2216000 hospitalized patients in the United States had serious ADRs, and 106000 were fatal, making these reactions the fourth to sixth leading cause of death in this country. 9 Physicians should have thorough knowledge of the therapeutic and possible adverse effects of prescribed medications, but drug labeling in package inserts may not provide adequate information. Our study has shown that, in a pediatric office, rashes may occur in 7.3% of children following the administration of oral antibiotics but only in less than 3% of exposures to common oral antibiotics when considered per written prescription. However, these rashes are more likely to occur with cefaclor, followed by sulfonamides and penicillins. We also found that in the pediatric outpatient setting, these rashes are most likely to be minor and non-life threatening. However, they may cause discomfort, parental anxiety, frequent visits to the physician, and additional cost. 1 In addition, these reactions indi- rectly may impair good therapeutic outcomes and contribute to the problem of antibiotic-resistant strains.
Kramer et al, 1 in a prospective study documenting ADRs to prescription and nonprescription medications during a period of 1 year in a general pediatric group practice, reported 473 ADRs (11.1%) from 4244 separate courses of drug therapy. The most common ADRs were gastrointestinal tract complaints and rashes associated with antibiotics. Of those 4244 courses of drug prescriptions, oral antibiotics accounted for 64%, and 96% of the prescribed 2714 courses of oral antibiotics were penicillins, sulfonamides, and cephalosporins. The design of that study did not allow determination of the frequency of rashes associated with the different orally administered antibiotics. Mitchell et al 5 reported that 2% of 6546 admissions of children to 4 teaching and 3 community hospitals were due to ADRs, while 2 of the children died of ADRs (the only antibiotic-related death was attributed to theophylline toxicity from a theophylline and erythromycin interaction). In contrast, none of the children in our study died or required hospitalization for antibiotic-associated rashes.
The label for cefaclor states that the rate of hypersensitivity reactions is 1.5%. 10 Specifically, morbilliform rashes, urticaria, and serum sickness are said to occur in 1%, less than 0.5%, and 0.02% to 0.5% of persons, respectively, while Stevens-Johnson syndrome and toxic epidermal necrolysis are rare. None of our 527 patients who received cefaclor developed StevensJohnson syndrome or toxic epidermal necrolysis, but 12.3% had various other rashes. Ten (1.90%) developed definite or probable SSLRs to that drug compared with penicillins (0.35%), sulfonamides (0.36%), and other cephalosporins (0.10%). A review 11 of the US Food and Drug Administration's spontaneous adverse drug report database noted that SSLRs constituted 25% of such reports for cefaclor. Other than cefaclor, cephalosporin antibiotics are associated with far fewer rashes than any of the penicillins, 12, 13 as shown in our study (Table 2 ).
More than 7% of patients prescribed oral amoxicillin or penicillin in our study developed rashes. In a comprehensive drug surveillance system that monitored *Definite SSLR is defined as antibiotics taken for 7 days or more with rash, fever, and joint pains or swelling; probable SSLR, antibiotics taken for less than 7 days, with rash, fever, and joint pains or swelling.
†PϽ.001 for cefaclor vs penicillins, cefaclor vs sulfonamides, and cefaclor vs other cephalosporins; P = .18 for penicillins vs other cephalosporins; P = .92 for penicillins vs sulfonamides; and P = .17 for sulfonamides vs other cephalosporins.
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